ArticleAnnals of surgical oncology2014
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients.
Article in Annals of surgical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 155 citations in OpenAlex.
- Predictive Values of Pathological and Clinical Risk Factors for Positivity of Sentinel Lymph Node Biopsy in Thin Melanoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique.World journal of surgical oncology · 2015Trial
- Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients.PloS one · 2015Trial
- Improving Risk Stratification for SLNB in Elderly Patients With Melanoma: The SENTINOLD Nomogram.International journal of dermatology · 2026Article
- Review
- Editorial: The Critical Role of Surgery for Local Disease Control and Nodal Assessment in Merkel Cell Carcinoma.Annals of surgical oncology · 2026Article
- Single-cell multi-omics dissection of RevitalAge Markers uncovers age-dependent immunotherapy resistance and druggable targets in melanoma.Biology direct · 2026Article
- The Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma.European journal of epidemiology · 2025Article
- Non-proportional hazards model with a PVF frailty term: application with a melanoma dataset.Journal of applied statistics · 2025Article
- The Utility of Sentinel Lymph Node Biopsy in Elderly Patients with Melanoma.Annals of surgical oncology · 2024Article
- Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm).Annals of surgical oncology · 2023Article
- Primary Melanoma Histopathologic Predictors of Sentinel Lymph Node Positivity: A Proposed Scoring System for Risk Assessment and Patient Selection in a Clinical Setting.Medicina (Kaunas, Lithuania) · 2023Article
- Article
- Prediction of distant metastasis and specific survival prediction of small intestine cancer patients with metastasis: A population-based study.Cancer medicine · 2023Article
- Article
- The role of imaging and sentinel lymph node biopsy in patients with T3b-T4b melanoma with clinically negative disease.Frontiers in oncology · 2023Article
- Tissue Biomarkers Predicting Lymph Node Status in Cutaneous Melanoma.International journal of molecular sciences · 2022Review
- Using Gene Expression Profiling to Personalize Skin Cancer Management.The Journal of clinical and aesthetic dermatology · 2022Review
- Sentinel Lymph Node Biopsy vs. Observation in Thin Melanoma: A Multicenter Propensity Score Matching Study.Journal of clinical medicine · 2021Article
- Use and Costs of Sentinel Lymph Node Biopsy in Non-Ulcerated T1b Melanoma: Analysis of a Population-Based Registry.Annals of surgical oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 18 institutions in 4 countries.
Funding
Abstract
purposeWe have previously reported that older patients with clinical stage I and II primary cutaneous. Melanoma had lower survival rates compared to younger patients. We postulated that the incidence of nodal metastasis would therefore be higher among older melanoma patients.
methodsThe expanded American Joint Committee on Cancer melanoma staging database contains a cohort of 7,756 melanoma patients who presented without clinical evidence of regional lymph node or distant metastasis and who underwent a sentinel node biopsy procedure as a component of their staging assessment.
resultsAlthough older patients had primary melanoma features associated with more aggressive biology, we paradoxically observed a significant decrease in the incidence of sentinel node metastasis as patient age increased. Overall, the highest incidence of sentinel node metastasis was 25.8 % in patients under 20 years of age, compared to 15.5 % in patients 80 years and older (p < 0.001). In contrast, 5-year mortality rates for clinical stage II patients ranged from a low of 20 % for those 20-40 years of age up to 38 % for those over 70 years of age. Patient age was an independent predictor of sentinel node metastasis in a multifactorial analysis (p < 0.001).
conclusionsPatients with clinical stage I and II melanoma under 20 years of age had a higher incidence of sentinel lymph node metastasis but, paradoxically, a more favorable survival outcome compared to all other age groups. In contrast, patients >70 years had the most aggressive primary melanoma features and a higher mortality rate compared to all other age groups but a lower incidence of sentinel lymph node metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.